By Drug Target Review2025-09-09T08:30:56
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2023-07-11T16:13:06
Sponsored by Agilent
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud